Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.
Covered in this story
What has happened since
- Galectin Therapeutics is down 5.9% since this was published, 14 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $GALT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Galectin Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.